Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VNDABearishIndustry Newsnews

High materiality8/10

Vanda's VQW-765 Phase III failure triggers hold and near-term VNDA downside

Oct 14, 2026, 5:23 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Phase III failure undermines probability of approval for a late-stage drug, raises R&D costs and potential need for strategic actions; historical biotech failures after Phase III typically lead to stock decline in weeks to months.

AI summary

What happened, with direct paths to the underlying reporting

Vanda Pharmaceuticals reported that its Phase III VP-VQW-765-3201 trial for social anxiety disorder did not meet the primary endpoint, and the program is on hold pending full data analysis. The failure undermines the asset’s prospects and could pressure VNDA’s near-term valuation, while management evaluates the pipeline and potential strategic options, including licensing or divestiture.

Phase III VP-VQW-765-3201 failed to meet primary endpoint.
Study showed no significant SUDS improvement vs placebo (p=0.8899 for females).
VQW-765 program on hold pending full dataset analysis.
Earlier Phase II suggested lower TSST stress, not replicated.
VNDA remains focused on late-stage pipeline and strategic options.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.